Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis.
暂无分享,去创建一个
Yusuke Nakamura | T. Katagiri | S. Miyano | S. Imoto | R. Yamaguchi | K. Rokutan | Y. Miyoshi | K. Kiyotani | M. Shimada | T. Yoshimaru | Masato Komatsu | T. Matsuo | M. Sasa | T. Tanahashi | A. Saito
[1] Jungsuk An,et al. Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype , 2012, Histopathology.
[2] Ki-Chun Yoo,et al. PTTG1 Oncogene Promotes Tumor Malignancy via Epithelial to Mesenchymal Transition and Expansion of Cancer Stem Cell Population* , 2012, The Journal of Biological Chemistry.
[3] T. Putti,et al. The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast Cancer , 2012, PloS one.
[4] S. Law,et al. The ECM protein LTBP‐2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome , 2011, International journal of cancer.
[5] A. Tangoku,et al. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. , 2011, Anticancer research.
[6] George S. Krasnov,et al. Differential Expression of CHL1 Gene during Development of Major Human Cancers , 2011, PloS one.
[7] J. Mackey,et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.
[8] T. Arumugam,et al. S100P: a novel therapeutic target for cancer , 2011, Amino Acids.
[9] F. Lallemand,et al. Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy , 2011, Molecular Cancer.
[10] R. Cardiff,et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. , 2010, Cancer research.
[11] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[12] Per Karlsson,et al. Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma , 2010, Clinical Cancer Research.
[13] M. Nagino,et al. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.
[14] Jian-ming Li,et al. A five‐gene signature as a potential predictor of metastasis and survival in colorectal cancer , 2010, The Journal of pathology.
[15] J. Baselga,et al. Management of breast cancer with targeted agents: importance of heterogenicity , 2010, Nature Reviews Clinical Oncology.
[16] W. Jin,et al. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs , 2010, Breast Cancer Research and Treatment.
[17] J. Gray,et al. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer , 2010, Breast Cancer Research.
[18] Yusuke Nakamura,et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. , 2009, Cancer research.
[19] R. Bataille,et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer , 2009, British Journal of Cancer.
[20] Ming-Tzu Tsai,et al. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. , 2009, Cancer research.
[21] M. Nagino,et al. Nek2 as a novel molecular target for the treatment of breast carcinoma , 2009, Cancer science.
[22] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[23] J. Pumphrey,et al. The TRAIL to targeted therapy of breast cancer. , 2009, Advances in cancer research.
[24] T. Katagiri,et al. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells , 2008, Oncogene.
[25] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[27] Paul S Mischel,et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells , 2008, Journal of neuroscience research.
[28] A. Desai,et al. KNL1 and the CENP-H/I/K complex coordinately direct kinetochore assembly in vertebrates. , 2007, Molecular biology of the cell.
[29] Yusuke Nakamura,et al. Involvement of kinesin family member 2C/mitotic centromere‐associated kinesin overexpression in mammary carcinogenesis , 2007, Cancer science.
[30] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[31] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[32] Daniel Birnbaum,et al. Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.
[33] Yusuke Nakamura,et al. Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells , 2007, Cancer science.
[34] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[35] Yusuke Nakamura,et al. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family , 2007, Breast Cancer Research.
[36] S. Horvath,et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.
[37] Yusuke Nakamura,et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.
[38] Q. Tao,et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. , 2006, Carcinogenesis.
[39] A. Fry,et al. Nek2 kinase in chromosome instability and cancer. , 2006, Cancer letters.
[40] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[41] C. Pilarsky,et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. , 2004, Neoplasia.
[42] J. Minna,et al. Molecular Detection of Noninvasive and Invasive Bladder Tumor Tissues and Exfoliated Cells by Aberrant Promoter Methylation of Laminin-5 Encoding Genes , 2004, Cancer Research.
[43] J. Isola,et al. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? , 2003, Clinical breast cancer.
[44] T. Tomonaga,et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. , 2003, Cancer research.
[45] Emanuel F. Petricoin,et al. Medical applications of microarray technologies: a regulatory science perspective , 2002, Nature Genetics.
[46] A. Báez,et al. Cenp‐F gene amplification and overexpression in head and neck squamous cell carcinomas , 2001, Head & neck.
[47] H. Ford,et al. Cell Cycle-regulated Phosphorylation of the Human SIX1 Homeodomain Protein* , 2000, The Journal of Biological Chemistry.
[48] D. Glover,et al. Abnormal spindle protein, Asp, and the integrity of mitotic centrosomal microtubule organizing centers. , 1999, Science.
[49] E. Tan,et al. Autoantibody to centromere (kinetochore) in scleroderma sera. , 1980, Proceedings of the National Academy of Sciences of the United States of America.